纳入中度HBV DNA水平的PAGE-B评分可预测进入HBeAg阳性慢性乙型肝炎患者的肝细胞癌风险
这项多中心队列研究纳入韩国23家三级大学附属医院2012至2020年间3585例HBeAg阳性、非肝硬化、从慢性感染进入慢性乙型肝炎并开始恩替卡韦或富马酸替诺福韦二吡呋酯抗病毒治疗的患者,基于多变量Cox模型开发并验证了新的PAGED-B评分。训练队列2367例中,年龄、性别、血小板、糖尿病和中度HBV DNA水平(5.00-7.99 log10 IU/ml)与肝细胞癌发生独立相关,PAGED-B评分预测5年肝细胞癌发生的时间依赖AUROC为0.81;验证队列1218例中AUROC为0.85,显著高于其他风险评分。
要点
- PAGED-B评分基于年龄、性别、血小板、糖尿病和中度HBV DNA水平(5.00-7.99 log10 IU/ml)五个预测因子。
- 训练队列中PAGED-B评分预测5年肝细胞癌发生的时间依赖AUROC为0.81,验证队列为0.85。
- 验证队列中PAGED-B的AUROC显著高于PAGE-B、mPAGE-B、CAMD和REAL-B等其他风险评分。
核心结论
- 新建立的PAGED-B评分可能有助于在从慢性感染进入HBeAg阳性慢性乙型肝炎时进行肝细胞癌风险分层。
研究设计与样本
- 多中心队列研究,纳入韩国23家三级大学附属医院2012至2020年间3585例HBeAg阳性、非肝硬化、从慢性感染进入慢性乙型肝炎并开始恩替卡韦或富马酸替诺福韦二吡呋酯抗病毒治疗的患者。
- 基于多变量Cox模型在训练队列(n=2367)中开发新肝细胞癌风险评分PAGED-B,并进行bootstrap抽样的内部验证和外部验证(验证队列,n=1218)。
主要发现
- 60例(1.7%)患者发生肝细胞癌(中位随访5.4年)。
- 训练队列中,年龄、性别、血小板、糖尿病和中度HBV DNA水平(5.00-7.99 log10 IU/ml)与肝细胞癌发生独立相关。
- PAGED-B评分(基于上述五个预测因子)预测5年肝细胞癌发生的时间依赖AUROC为0.81。
- 验证队列中PAGED-B的AUROC为0.85,显著高于PAGE-B、mPAGE-B、CAMD和REAL-B等其他风险评分。
- 按PAGED-B评分分层,高风险患者的肝细胞癌风险显著高于低风险患者(训练队列亚分布风险比=8.43,验证队列=11.59,均p<0.001)。
关键数值与推荐
- PAGED-B评分范围为0至12分,低风险<7分,高风险≥7分。
- PAGED-B评分纳入基线中度HBV DNA水平(5-8 log10 IU/ml)。
临床怎么用
- 基于患者从慢性感染进入慢性乙型肝炎时的年龄、性别、糖尿病状态、血小板计数和中度DNA水平(5-8 log10 IU/ml),PAGED-B评分是预测HBeAg阳性进入慢性乙型肝炎患者抗病毒治疗前5年肝细胞癌发生的可靠且易于获取的风险评分。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Recent studies reported that moderate HBV DNA levels are significantly associated with hepatocellular carcinoma (HCC) risk in hepatitis B e antigen (HBeAg)-positive, non-cirrhotic patients with chronic hepatitis B (CHB). We aimed to develop and validate a new risk score to predict HCC development using baseline moderate HBV DNA levels in patients entering into HBeAg-positive CHB from chronic infection. METHODS: This multicenter cohort study recruited 3,585 HBeAg-positive, non-cirrhotic patients who started antiviral treatment with entecavir or tenofovir disoproxil fumarate at phase change into CHB from chronic infection in 23 tertiary university-affiliated hospitals of South Korea (2012-2020). A new HCC risk score (PAGED-B) was developed (training cohort, n = 2,367) based on multivariable Cox models. Internal validation using bootstrap sampling and external validation (validation cohort, n = 1,218) were performed. RESULTS: Sixty (1.7%) patients developed HCC (median follow-up, 5.4 years). In the training cohort, age, gender, platelets, diabetes and moderate HBV DNA levels (5.00-7.99 log10 IU/ml) were independently associated with HCC development; the PAGED-B score (based on these five predictors) showed a time-dependent AUROC of 0.81 for the prediction of HCC development at 5 years. In the validation cohort, the AUROC of PAGED-B was 0.85, significantly higher than for other risk scores (PAGE-B, mPAGE-B, CAMD, and REAL-B). When stratified by the PAGED-B score, the HCC risk was significantly higher in high-risk patients than in low-risk patients (sub-distribution hazard ratio = 8.43 in the training and 11.59 in the validation cohorts, all p <0.001). CONCLUSIONS: The newly established PAGED-B score may enable risk stratification for HCC at the time of transition into HBeAg-positive CHB. IMPACT AND IMPLICATIONS: In this study, we developed and validated a new risk score to predict hepatocellular carcinoma (HCC) development in patients entering into hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) from chronic infection. The newly established PAGED-B score, which included baseline moderate HBV DNA levels (5-8 log10 IU/ml), improved on the predictive performance of prior risk scores. Based on a patient's age, gender, diabetic status, platelet count, and moderate DNA levels (5-8 log10 IU/ml) at the phase change into CHB from chronic infection, the PAGED-B score represents a reliable and easily available risk score to predict HCC development during the first 5 years of antiviral treatment in HBeAg-positive patients entering into CHB. With a scoring range from 0 to 12 points, the PAGED-B score significantly differentiated the 5-year HCC risk: low <7 points and high ≥7 points.
引用
- Chun HS, Papatheodoridis GV, Lee M, et al. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B. J Hepatol. 2023. PMID: 37734683. doi:10.1016/j.jhep.2023.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。